By Notice dated August 19, 2003, and published in the Federal Register on September 2, 3003, (68 FR 52224), Bristol Myers Squibb Pharma Company, 1000 Stewart Avenue, Garden City, New York 11530, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of Oxycodone (9143), a basic class of controlled substance listed in Schedule II.
The firm plans to manufacture the controlled substance to make finished products.
No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Bristol Myers Squibb Pharma Company to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Bristol Myers Squibb Pharma Company to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed is granted.Start Signature
Dated: December 8, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 04-721 Filed 1-13-04; 8:45 am]
BILLING CODE 4410-09-M